Mirna Therapeutics Inc. (NASDAQ:MIRN) was downgraded by equities research analysts at Cantor Fitzgerald from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

Several other equities research analysts have also weighed in on the company. Oppenheimer Holdings Inc. lifted their price objective on Mirna Therapeutics from $7.00 to $13.00 and gave the stock an “outperform” rating in a report on Tuesday, August 16th. Zacks Investment Research raised Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Wednesday, September 7th. Leerink Swann lowered Mirna Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $10.00 to $4.00 in a report on Monday, August 15th. HC Wainwright started coverage on Mirna Therapeutics in a report on Monday, September 12th. They issued a “buy” rating and a $6.00 price objective for the company. Finally, Citigroup Inc. lowered Mirna Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $7.00 to $4.50 in a report on Tuesday, August 16th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $7.38.

Mirna Therapeutics (NASDAQ:MIRN) opened at 2.46 on Wednesday. The firm’s market cap is $51.25 million. Mirna Therapeutics has a 52 week low of $2.21 and a 52 week high of $11.01. The firm’s 50-day moving average price is $3.17 and its 200 day moving average price is $4.12.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/mirna-therapeutics-inc-mirn-downgraded-by-cantor-fitzgerald-to-hold.html

About Mirna Therapeutics

Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.

5 Day Chart for NASDAQ:MIRN

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.